Claus Sundgreen, MD, TikoMed’s Consultant Medical Director, will be presenting at ALS ONE‘s annual Symposium. Don’t miss his highly interesting and informative talk titled: ILB®: A Novel Therapeutic Agent for ALS Targeting Excitotoxicity, Mitochondrial Dysfunction, and InflammationFriday, November 17th2:25-2:45pm EST #ALS#neurodegeneration
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board. Adriano Chiò is a neurologist
Viken – 25 oktober 2023 – Det svenska biofarmabolaget TikoMed AB tillkännagav idag utnämningen av professor Adriano Chiò, verksam vid universitetet i Turin och sjukhuset Città della Salute e della Scienza, som den fjärde medlemmen i TikoMeds nybildade vetenskapliga råd (Scientific Advisory Board – SAB). Adriano Chiò är neurolog och
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed
Viken – 11 oktober 2023 – Det svenska biofarmabolaget TikoMed AB tillkännagav idag utnämningen av Professor Jeremy Shefner, MD, PhD verksam vid the Gregory W. Fulton ALS & Neuromuscular Disease Center och the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA som den tredje medlemmen i TikoMeds
Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board. Dr. Ingre runs the ALS clinic at